MedXCell SA is proud to announce the arrival of Gabriel Baertschi as a new member of the Board

Montreux, Switzerland | May 17, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and accessible new therapies utilizing the unique powers of living cells, announced the arrival of Gabriel Baertschi as the latest member of its Board.

Gabriel Baertschi (born in 1974, Switzerland) has over 20 years’ experience in the pharmaceutical industry, with expertise across multiple therapeutics areas. He has successfully launched mega brands including oncology products. He joined Grünenthal (fully integrated research-based company) in October 2016 as Chief Executive Officer and Chairman of the Corporate Executive Board. As per reference, the Group had gross revenue of 1,4B euros in 2019, its products are available in 100 countries and employs more than 4700 people. Furthermore, Gabriel Baertschi was AstraZeneca’s former Company President in Japan and Germany and held various global commercial strategic roles.

The collaboration between an early and innovative start-up like MedXCell SA and a strategic pharmaceutical expert like Gabriel Baertschi, who comes with development and commercializing expertise as well as crafting partnerships and deal making track record, is a promising and winning combo that will rapidly optimize the development of the company.

In an era where health has become the number one subject, and competition in the biotech industry is stronger than ever, the company keeps in mind that its main goal is to provide efficient, affordable, and ethically made treatments for everyone. In this sense, Lionel Brodard, CFO of MedXCell SA said “Having someone like Gabriel, who seen it all, joining our team is an honor and it pushes us forward. It confirms that our model is different from the others and that there’s endless hope in creating the best products to help and improve the life of patients”.

Gabriel Baertschi added “I am passionate about delivering medicine in areas of high unmet medical needs. Contributing to the growth of MedXCell is an energizing mission!”.

Lionel Brodard, CFO

+41 21 963 06 53